Literature DB >> 25239082

How much oxycodone is needed for adequate analgesia after breast cancer surgery: effect of the OPRM1 118A>G polymorphism.

Kristiina Cajanus1, Mari A Kaunisto, Minna Tallgren, Ritva Jokela, Eija Kalso.   

Abstract

UNLABELLED: Most clinically used opioids are mu-opioid receptor agonists. Therefore, genetic variation of the OPRM1 gene that encodes the mu-opioid receptor is of great interest for understanding pain management. A polymorphism 118A>G (rs1799971) within the OPRM1 gene results in a missense mutation and affects the function of the receptor. We studied the association between the 118A>G polymorphism and oxycodone analgesia and pain sensitivity in 1,000 women undergoing breast cancer surgery. Preoperatively, experimental cold and heat pain sensitivities were tested. Postoperative pain was assessed at rest and during motion. Intravenous oxycodone analgesia was titrated first by a research nurse and on the ward using a patient-controlled analgesia device. The primary endpoint was the amount of oxycodone needed for the first state of adequate analgesia. For each patient, the 118A>G polymorphism was genotyped using the Sequenom MassARRAY (Sequenom, San Diego, CA). The association between this variant and the pain phenotypes was tested using linear regression. The 118A>G variant was associated significantly with the amount of oxycodone requested for adequate analgesia (P = .003, β = .016). Collectively, oxycodone consumption was highest in individuals having the GG genotype (.16 mg/kg), lowest for those with the AA genotype (.12 mg/kg), and moderate for those having the AG genotype (.13 mg/kg). Furthermore, the G allele was associated with higher postoperative baseline pain ratings (P = .001, β = .44). No evidence of association with other pain phenotypes examined was observed. PERSPECTIVE: This study demonstrates that the OPRM1 118A>G polymorphism was associated with the amount of oxycodone required in the immediate postoperative period. Although a significant factor for determining oxycodone requirement, the 118A>G polymorphism alone explained less than 1% of the variance. No association was found between 118A>G and experimental pain

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25239082     DOI: 10.1016/j.jpain.2014.09.002

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  12 in total

Review 1.  Value of Supportive Care Pharmacogenomics in Oncology Practice.

Authors:  Jai N Patel; Lauren A Wiebe; Henry M Dunnenberger; Howard L McLeod
Journal:  Oncologist       Date:  2018-04-05

Review 2.  Genetic Variants Associated with Cancer Pain and Response to Opioid Analgesics: Implications for Precision Pain Management.

Authors:  Gee Su Yang; Natalie M Barnes; Debra E Lyon; Susan G Dorsey
Journal:  Semin Oncol Nurs       Date:  2019-05-10       Impact factor: 2.315

Review 3.  Molecular Genetics and New Medication Strategies for Opioid Addiction.

Authors:  Yasmin L Hurd; Charles P O'Brien
Journal:  Am J Psychiatry       Date:  2018-08-02       Impact factor: 18.112

Review 4.  Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone.

Authors:  Mari Kinnunen; Panu Piirainen; Hannu Kokki; Pauliina Lammi; Merja Kokki
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

5.  Effect of preemptive analgesia with intravenous oxycodone in the patients undergoing laparoscopic resection of ovarian tumor.

Authors:  Na Wang; Yuantao Wang; Lei Pang; Jinguo Wang
Journal:  Pak J Med Sci       Date:  2015 Mar-Apr       Impact factor: 1.088

6.  High-dose OxyContin to treat pain associated with bone metastasis in patients with small-cell lung cancer: a case study report.

Authors:  Tao Zhou; Xia Zhang; Yan Dong; Feifei Zhuang; Fengquan Jiang; Jinming Yu; Bin Zhang
Journal:  Drug Des Devel Ther       Date:  2016-01-19       Impact factor: 4.162

7.  Oxycodone vs Sufentanil in Patient-Controlled Intravenous Analgesia After Gynecological Tumor Operation: A Randomized Double-Blind Clinical Trial.

Authors:  Sha-Jie Dang; Rui-Li Li; Jun Wang; Wen-Bin Zeng; Yun He; Hui-Yu Yue; Si-Yuan Li; Li-Chun Han
Journal:  J Pain Res       Date:  2020-05-05       Impact factor: 3.133

8.  Four single nucleotide polymorphisms in genes involved in neuronal signaling are associated with Opioid Use Disorder in West Virginia.

Authors:  Laura R Lander; Vincent Setola; Shane W Kaski; Stephan Brooks; Sijin Wen; Marc W Haut; David P Siderovski; James H Berry
Journal:  J Opioid Manag       Date:  2019 Mar-Apr

Review 9.  Pharmacogenomics of oxycodone: a narrative literature review.

Authors:  Nelly N Umukoro; Blessed W Aruldhas; Ryan Rossos; Dhanashri Pawale; Janelle S Renschler; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2021-03-17       Impact factor: 2.533

10.  Oxycodone versus sufentanil in adult patient-controlled intravenous analgesia after abdominal surgery: A prospective, randomized, double-blinded, multiple-center clinical trial.

Authors:  Lichun Han; Yuqiang Su; Hongfei Xiong; Xiaoli Niu; Shajie Dang; Keqin Du; Quan Li; Jing Liu; Peng Zhang; Siyuan Li
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.